SCHEMBL23327641

SCHEMBL23327641

CC(C)(C)OC(=O)N1CCC2CC21c1cc(F)ccc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.40
APP P05067 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
DRD2 P14416 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
SLC6A2 P23975 1/20 0.39
HRH2 P25021 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR7 P34969 1/20 0.39
DRD3 P35462 1/20 0.39
OPRK1 P41145 1/20 0.39
HTR2B P41595 1/20 0.39
PSEN1 P49768 1/20 0.39
SLC6A3 Q01959 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23327607 0.82 PSEN1 (0.33) HSD11B1PSEN1KDM1AMEN1KMT2A
SCHEMBL23327605 0.80 CCNT1 (0.41) SMN1; SMN2GPR119MEN1KMT2A
SCHEMBL30082706 0.80 CCNT1 (0.41) SMN1; SMN2GPR119MEN1KMT2A
SCHEMBL23327594 0.75 CCNT1 (0.37) SMN1; SMN2GPR119
SCHEMBL30082708 0.75 CCNT1 (0.37) SMN1; SMN2GPR119
SCHEMBL1429735 0.74 PSEN1 (0.42) SMN1; SMN2APPHTR1AADRA2ADRD2
SCHEMBL17353253 0.73 PSEN1 (0.42) SMN1; SMN2APPHTR1AADRA2ADRD2
SCHEMBL28474971 0.72 PSEN1 (0.37) HSD11B1HTR2AHTR2CPSEN1
SCHEMBL27101250 0.72 PSEN1 (0.37) HSD11B1HTR2AHTR2CPSEN1
SCHEMBL26181053 0.72 PSEN1 (0.37) HSD11B1HTR2AHTR2CPSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11555042-B2 Macrocyclic compounds as TRK kinases inhibitors FOCHON BIOSCIENCES, LTD. (CN) 2023-01-17 US disclosed
US-20210139506-A1 MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS FOCHON PHARMACEUTICALS, LTD. (CN) 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139506-A1 MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS PLK2, ERBB3, DMPK HSD11B1 3032/4885SMN1; SMN2 2669/4885APP 3161/4885
US-11555042-B2 Macrocyclic compounds as TRK kinases inhibitors PLK2, ERBB3, DMPK HSD11B1 3032/4885SMN1; SMN2 2669/4885APP 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.